Eczema (or atopic dermatitis) affects millions of people, especially children under the age of six.

Long-term inflammation of the skin causes the skin to become red and dry and it starts to ooze and itch, which makes life very uncomfortable.

There is currently no cure for the condition, only ways to treat it – but the medication that is available is surprisingly effective in reducing the signs and symptoms of moderate to severe pain in children under the age of six.

The first time is complicated Biological medicine Thus tested on this age group.

The drug in question dupilumab. In a new study, 162 North American and European children aged 6 months to 6 years with moderate to severe eczema were given either dupilumab or a placebo for 16 weeks.

More than half of the children given the drug had a 75 percent reduction in symptom severity. The itching is significantly reduced, and the children can sleep better.

“Preschoolers scratch constantly, wake up with their parents often, have tantrums and have a reduced ability to do things that other children their age can do, improve until they sleep through the night, change their personality, and show pain. Normal life – as babies and children says dermatologist Amy Paller from Northwestern University in Illinois.

Dupilumab targets an immune-inflammatory pathway important in allergies and is already used in older children and adults to treat asthma, nasal polyps and other allergic conditions.

Until now, it had not been proven safe or effective for children under the age of six. 19 percent This demographic is considered to have eczema 85-90 percent People who have experienced eczema in their life will see the first symptoms before the age of five.

About a third of eczema in this age group has moderate to severe pain, accompanied by debilitating itching: these children cannot sleep properly, which has all kinds of knock-on effects and consequences.

While immunosuppressants such as oral steroids are used for severe eczema, there are concerns about their appropriateness in young children – both short-term side effects and long-term health problems. As a paler.

“The group we are most concerned about safety – the under-fives – has not been tested and cannot be found [dupilumab]” Paller says. “For these young children, the effect on most children is remarkable and at least as good as what we’ve seen with immunosuppressive drugs.”

Dupilumab already has a safety profile labeled “very excellent,” and no additional laboratory tests are required. It is now available for children as young as 6 months of age, and either a parent or healthcare professional can administer the drug through a monthly injection.

In addition, the researchers think that this may have immunity. Because it takes such a powerful approach to calming the immune system’s inflammatory response, there’s a good chance it can also protect against other allergic issues later in life.

Dupilumab may be useful in treating other health conditions in young children, the researchers suggest — although more studies are needed to determine how effective it might be.

“The ability to take this medication will greatly improve the quality of life for infants and young children suffering from this disease.” Paller says.

“Atopic dermatitis or eczema is more than itchy skin. It is a terrible disease. The quality of life of severe eczema – not only for the child, but also for the parents – is equal to many life-threatening diseases.”

The study was sponsored by Regeneron Pharmaceuticals and Sanofi, who jointly developed dupilumab, and the study was conducted in 2010. The Lancet.

Leave a Reply

Your email address will not be published.